Skip to content

Upadacitinib

Published: August 9, 2026Updated: August 9, 2026

Rinvoq (upadacitinib) is a prescription brand-name medication classified as a Janus kinase (JAK) inhibitor. It is used to treat adults with certain inflammatory conditions by targeting the immune system to reduce inflammation. Rinvoq is available as an oral extended-release tablet taken once daily.

Quick summary

Rinvoq is a JAK inhibitor medication used to treat inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis by reducing immune system activity.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 9, 2026Editorial policy

Key facts at a glance

RxNorm
2196895
Generic
Rinvoq
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Rinvoq is FDA-approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease when other treatments have not been adequate.

Rinvoq contains the active ingredient upadacitinib, which works by inhibiting Janus kinase (JAK) enzymes. These enzymes are involved in the inflammatory signaling pathways of the immune system. By blocking JAK activity, Rinvoq helps reduce inflammation and the symptoms associated with inflammatory conditions.

Rinvoq is a brand-name medication with no generic equivalent currently available. Common side effects may include upper respiratory infections, acne, headache, and increased cholesterol levels. As a JAK inhibitor, it may increase the risk of serious infections, cancer, and cardiovascular events. Patients should be monitored for these potential risks during treatment.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy